What is hyper CVAD chemotherapy?

An abbreviation for a chemotherapy combination used to treat some types of acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). Hyper-CVAD includes the drugs cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride (Adriamycin), and dexamethasone.

What is Gmall protocol?

The GMALL study group developed these protocols based on concepts employed successfully in the treatment of paediatric mature B-ALL. All used short, alternating cycles of intensive chemotherapy (in an ABABAB pattern) that included high doses of methotrexate and cyclophosphamide.

How long is induction therapy for ALL?

Induction therapy usually lasts for 29 days followed by a 1-week rest from chemotherapy. During induction, drugs will be given intravenously (IV) or through an intrathecal (IT) or orally (by mouth):

What is remission induction chemotherapy?

Listen to pronunciation. (reh-MIH-shun in-DUK-shun THAYR-uh-pee) Initial treatment with anticancer drugs to decrease the signs or symptoms of cancer or make them disappear.

How many cycles of chemo are there?

During a course of treatment, you usually have around 4 to 8 cycles of treatment. A cycle is the time between one round of treatment until the start of the next. After each round of treatment you have a break, to allow your body to recover.

Does chemo help leukemia?

Chemo drugs travel through the bloodstream to reach cancer cells all over the body. This makes chemo useful for cancers such as leukemia that has spread throughout the body. Chemo is the main treatment for just about all people with acute lymphocytic leukemia (ALL).

How does intrathecal chemo work?

It has a catheter (tube) attached that allows medication to reach an open space in your brain where CSF flows. When chemotherapy medication is injected into the reservoir, it flows into the CSF without the need for spinal taps each time. This makes it a good option for people who need multiple treatments.

What kind of chemotherapy is used for autologeic SCT?

Maintenance therapy was planned after autologous SCT, whereas no systematic maintenance was planned after allogeneic SCT. Patients who failed to achieve MMolR after cycle 2 were further treated with imatinib combined with chemotherapy according to the more intense cyclophosphamide/vincristine/doxorubicin/dexamethasone protocol (hyperCVAD). 15

What is GRAaph for acute lymphoblastic leukemia?

GRAAPH: Percentage of patients with minimum residual disease (MRD) < 10-4 after induction and/or consolidation (= salvage) [ Time Frame: January 2014 ] Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: January 2014 ]

Who are the patients in the graaph-2005 study?

The GRAAPH-2005 study was conducted in 60 centers in France and Switzerland. Patients aged 18 to 59 years with newly diagnosed Ph+ and/or BCR-ABL1 –positive ALL were eligible.